DMAA DMAA
Company Profile ↓Company Overview
DMAA (DMAA) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +4.28% |
| 6 Months: | +2.59% |
| 3 Months: | +1.32% |
| 1 Month: | +0.47% |
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)68.20 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Income | -144.93K | -330.93K | -131.92K | -263.70K | -143.30K |
| Net Income | -144.93K | 1.25M | 2.29M | 2.18M | 1.97M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2025 |
|---|---|
| Operating Income | -2.82M |
| Net Income | 5.94M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Total Assets | 550.82K | 239.92M |
| Total Equity | -244.84K | -7.26M |
| Total Liabilities | 795.67K | 7.28M |
| Current Liabilities | 795.67K | 376.17K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2025 |
|---|---|
| Operating Cash Flow | -539.19K |
| Investing Cash Flow | -231.15M |
| Financing Cash Flow | 231.69M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2025 |
|---|---|
| Gross Margin % | - |
| Operating Margin % | - |
| Net Margin % | - |
| ROE % | -81.8% |
| ROCE % | -1.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DMAA
Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) is definitely on the radar of institutional investors who own 38% of the company
NasdaqGM:DMAA 1 Year Share Price vs Fair Value Explore Drugs Made In America Acquisition's Fair Values from the...
DMAA — Frequently Asked Questions
What is the current share price of DMAA?
As of 2026-08-05 17:25 PDT, DMAA trades at $10.71 on NASDAQ/NYSE. Its 52-week range is $10.23 to $10.71.
What is the return on equity (ROE) of DMAA?
DMAA has a return on equity (ROE) of -81.78%. Its return on capital employed (ROCE) is -1.18%.
Is DMAA a good stock to buy?
This page provides a data-driven analysis of DMAA, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.